Evidence from epidemiological and laboratory studies, as well as randomized placebo-controlled 31 trials, suggests supplementation with n-3 polyunsaturated fatty acids (PUFAs) may be efficacious 32 for treatment of major depressive disorder (MDD). The mechanisms underlying n-3 PUFAs 33 potential therapeutic properties remain unknown. There are suggestions in the literature that glial 34 hypofunction is associated with depressive symptoms and that antidepressants may normalize 35 glial function. In this study, iPSC-derived neuronal stem cell lines were generated from 36 individuals with MDD. Astrocytes differentiated from patient-derived neuronal stem cells 37 (iNSCs) were verified by GFAP. Cells were treated with eicosapentaenoic acid (EPA), 38 docosahexaenoic acid (DHA) and stearic acid (SA). During astrocyte differentiation, we found 39 that n-3 PUFAs increased GFAP expression and GFAP positive cell formation. BDNF and 40 GDNF production were increased in the astrocytes derived from patients subsequent to n-3 41 PUFA treatment. Stearic Acid (SA) treatment did not have this effect. CREB activity 42 (phosphorylated CREB) was also increased by DHA and EPA but not by SA. Furthermore, when 43 these astrocytes were treated with n-3 PUFAs, the cAMP antagonist, RP-cAMPs did not block n-44 3 PUFA CREB activation. However, the CREB specific inhibitor (666-15) diminished BDNF 45 and GDNF production induced by n-3 PUFA, suggesting CREB dependence. Together, these 46 results suggested that n-3 PUFAs facilitate astrocyte differentiation, and may mimic effects of 47 some antidepressants by increasing production of neurotrophic factors. The CREB-dependence 48 and cAMP independence of this process suggests a manner in which n-3 PUFA could augment 49 antidepressant effects. These data also suggest a role for astrocytes in both MDD and 50 antidepressant action. 51 52 53
Introduction GFAP (Cell signaling, Danvers, MA) antibodies in antibody dilution buffer (PBS, 1% BSA, 140 0.3% Triton X-100) buffer for overnight at 4 o C. Subsequently, the dishes were washed with 141 PBS four times and incubated with corresponding fluorochrome-conjugated secondary 142 antibodies in antibody dilution buffer (1:100) for 30 min. Mounting medium with DAPI (Vector) 143 was added to the dishes which were then imaged using confocal (LSM880) or epifluorescence 144 microscopy (Nikon). GFAP positive cells were counted under a 40X amplification field either 145 manually or in a Keyence (Itasca, IL) microscopy system.
146
Reverse transcription qualitative polymerase chain reaction 147 Total RNA from cells in 24-well cell culture plates was isolated using TRIZOL (Life 148 Technologies, Grand Island, NY, USA) following the manufacturer's instructions. Total RNA 149 (500 ng) was converted to cDNA by Superscript III Direct cDNA Synthesis System (Life 150 Technologies). Primers were designed to span exon-exon junction in order to preclude the 151 amplification of genomic DNA; primers for Human GFAP: forward, 5'-152 AGGGGGCAAAAGCACCAAAGA-3', reverse 5'CTGGGAAAATGA CGCAGTCCAG-3'; for 153 GDNF: forward, 5'-CCCGCCGCAAATATGCCAGA-3', reverse, 5'-GTTCCTCCTTGGTTT 154 CATAGCCC-3'; for BDNF, forward, 5'-GCCATCCCAAGGTCTAGGTG-3', reverse, 5'-155 GTGGGATGGTGGGCATAAGT-3'; for GAPDH; forward 5'-AACAGC GACACCC ACTCC 156 TC-3', reverse 5'-AGCCAAATTCGTTGTCATACCAGG-3'. The target amplicon sizes were After 30 days of differentiation, Astrocytes were treated with vehicle, DHA, EPA and SA as 163 described above for three days and then washed twice with ice-cold PBS prior to lysis. For the 164 standard method, cells were incubated on ice for 15 min in RIPA lysis buffer (Cell Signaling, 165 Danvers, MA) supplemented with Complete Protease Inhibitor Cocktail (Roche) and 166 phosphatase inhibitor (Thermo Scientific). Lysates were scraped into tubes and clarified by 167 centrifugation at 15000 x g for 10 min at 4 °C. Total protein concentrations of the supernatants 168 were determined by Pierce BCA Protein Assay (Thermo Scientific). 169 Reagents and equipment were purchased from Protein-Simple (San Jose, CA) unless stated 170 otherwise. All experiments followed the manufacturer's instructions. 1 µl 5X Fluorescent Master
171
Mix was added to each sample (4 µl). Samples were incubated at 95 °C for 5 min to denature.
172
Three microliters of each sample were loaded into the top-row wells of plates that were designed 173 to separate proteins of 12-230 kDa. Primary antibodies were diluted in Antibody Diluent as 174 follows: anti-BDNF (1:50), anti-GDNF (1:50) (Santa Cruz Biotechnology, Dallas, TX), anti- PUFAs treatment on the potential of Gαs-stimulated cAMP production was determined as 189 previous reported [31] . Astrocytes derived from the SSRI-sensitive patient were treated for 3 190 days, The average fluorescent density of selected cells (5-12 cell in each dish) were first 191 recorded, then cells were challenged with forskolin (2μM), and recording was continued.
192
Fluorescence density was normalized to baseline fluorescence for each experiment.
193

Statistical analysis 194
Statistical analyses were performed using the Prism 5 statistical package (GraphPad Software, 195 Inc., La Jolla, CA). All data were analyzed by Student's t-test or one-way analysis of variance 196 (ANOVA) with a Tukey's post hoc test. Data were expressed as Mean ± SD. A P value of<0.05
Results.
199 n-3 PUFAs facilitate astrocyte differentiation from iNSCs.
200
Decrease in astrocyte count and GFAP expression are seen at many brain regions in MDD post-201 mortem studies [32] [33] [34] [35] and animal models of depression [8] . A recent reprot suggested that 202 antidepressants could induce recovery of astrocytes in MDD, which could be a potential 203 mechanism for their anti-depression effect [8] . To test whether n-3 PUFAs affect astrocyte 204 formation, we observed the effect of n-3 PUFAs on astrocyte differentiation from iNSCs derived 205 from SSRI-sensitive or -resistant MDD subjects. First, patient-derived iNSCs were confirmed 206 with Sox2 and Pax6 co-immunostaining (Supplemental figure 1 A). The iNSCs were cultured 207 with astrocyte differentiation medium that contained DHA, EPA, SA or vehicle for 5 days, after 208 which cells underwent immunostaining with GFAP antibody. Note that GFAP staining is weak 209 in some cells after 5 day differentiation, but positive staining can be identified compared to cells 210 without expression of GFAP in the same field ( Figure 1B ). Cells with positive GFAP staining 211 were counted using confocal microscopy with 40x magnification. Four fields in each dish were 212 selected, randomly, for cell counting. Data indicated that the percentage of GFAP positive cells 213 in each 40X field, DHA or EPA treatment significantly increased the percentage of GFAP 214 positive cells compared to vehicle or SA treatment ( Figure 1B ). GFAP mRNA expression in 215 cells treated with DHA or EPA was almost two times higher than in vehicle control cells ( Figure   216 2 A). Furthermore, GFAP protein expression also increased in DHA or EPA treated cells 217 (Figure 2 B and C). We observed that differences in astrocyte differentiation between cells from 218 SSRI-sensitive and SSRI-resistant patients were not associated with n-3 PUFA treatment ( Figure   219 1 and 2). including SSRIs, could increase/restore the astrocyte counts or GFAP staining, which positively 280 correlated with attenuated "depression-indicators" in rodents [8] . These suggested a mechanism 281 for relief of depression by restoring astrocyte function. Some reports have indicated that n-3 282 PUFA treatment could impact the neuronal differentiation in primary cultured animal NSCs [51] .
283
A recent report indicated that DHA could enhance astrocyte-like morphologic formation in rat 284 astrocytes [52] . Here, taking the advantages of iPSC technology, the effect of n-3 PUFAs on 285 astrocyte differentiation from patient-derived iNSCs was tested. These data suggested that n-3 286 PUFAs could help restore the astrocyte population in MDD since n-3 PUFAs facilitated 287 astrocyte differentiation from patient-derived iNSC, as measured by an increase in GFAP 288 expression and GFAP positive cell counts compared to cells without n-3 PUFAs treatment. Thus, 289 gliogenesis may be relevant to therapeutic effects of n-3 PUFAs.
290
Human studies and animal models support relevance of neurotrophins to depression, 291 proposing that MDD is associated with decreased expression and/or function of BDNF and 292 GDNF, which can be alleviated with antidepressant therapy [53, 54] (though there are some 293 inconsistencies [38, 55] ). Furthermore, overexpression of BDNF in astrocytes leads to 294 antidepressant-like activity in mice [12] . Ketamine elevated BDNF in cultured mouse astrocyte, 295 and did this along a more rapid time course than monoamine-centric antidepressants [31] . N-3 296 PUFAs appeared to have similar effect on neurotrophin production as antidepressants. DHA and 297 EPA elevated BDNF and GDNF expression after three day treatment, but the saturated fatty acid, 298 SA, did not. This is similar to the treatment time required for antidepressants to translocate Gsα 299 from lipid rafts in C6 cells [18] . 300 It is worthy to mention that many (but not all) of these studies show greater efficacy of 301 EPA than DHA, while our studies suggest equal potency and efficacy for the two compounds 302 [14, 52, [56] [57] [58] . Note, however, that 1) the EPA-or DHA-"enriched" preparations used in 303 clinical studies are 80:20 mixtures of the two n-3 PUFA species and 2) orally-ingested 304 preparations are metabolized, something that does not occur in cell-culture medium 305 Several reports have shown that n-3 PUFAs could increase CREB expression and pCREB 306 in depression animal models [59] . In agreement with these reports, DHA and EPA increased 307 pCREB in patient-derived astrocytes, except that CREB expression was not altered by n-3 308 PUFAs in this study. The difference may result from using a different experimental model 309 (patient-derived astrocytes versus animal brain). CREB can be activated by cAMP-PKA 310 signaling pathway. The data from us and others have shown that chronic antidepressant treatment 311 increased adenylyl cyclase (AC) activity and cAMP in cells [31, 47, 60] . Phosphodiesterase 4 (a Recently, a study reported an increase of cAMP subsequent to brief EPA treatment in epithelial 317 cells [65]. We did not observe this in the human astrocyte preparation, so a cAMP increase induced by n-3 PUFAs might be cell type-dependent. Notably, data have indicated that 319 antidepressants, including ketamine, could increase cAMP by regulating interaction of Gαs with 320 adenylyl cyclase [31, 47] . N-3 PUFAS have similar effect; after 3-day treatment with n-3 321 PUFAs, Gαs-stimulated cAMP production was increased.
322
Consensus-binding sequences for CREB were identified in the promoter sequence of 323 either BDNF or GDNF genes [66] . Several studies suggested that elevation of expression of 324 BDNF or GDNF induced by antidepressants was dependent on CREB activity [37, 48] , however, 325 this has not been documented for n-3 PUFAs. In this study, the cell permeable CREB specific 326 inhibitor[49], indicated that pCREB mediated the elevation of BDNF and GDNF induced by 327 DHA or EPA in the astrocytes, even as the process was cAMP-independent.
328
Note that there are some limits to data interpretation in this study. Firstly, astrocytes 329 were derived from stem cells obtained from two subjects, one SSRI-sensitive and the other, 330 SSRI-resistant. Both appear to have the same response to n-3 PUFA treatment in astrocyte 331 differentiation, production of BDNF and GDNF, and activation of pCREB. It is possible that 332 these subjects would have both responded positively to n-3 PUFA, but this cannot be established.
333
In addition, though astrocytes derived from iPSCs provide many advantages for in vitro 334 depression studies, the induced astrocytes are generally considered developmentally immature.
335
These cells cannot predict the behavior of the subjects from whom they were derived.
336
In summary, this study suggests that DHA and EPA could facilitate astrocyte differentiation 337 from iNSCs and like antidepressants, increase BDNF and GDNF production in those cells. While 338 pCREB mediates this effect, it is cAMP-independent. The study further adds to a growing body 339 of work suggesting that iPSC technology is a useful tool to probe the cellular basis of MDD and 340 antidepressant response. This study also further establishes a role for astrocytes in depression 341 and antidepressant therapy. protein is essential for the upregulation of brain-derived neurotrophic factor transcription, Astrocytes from SSRI-sensitive subject-derived iNSC were treated with n-3 PUFAs for 1 day, 10 and cells were lysed and processed for capillary western assay. DHA, EPA and SA did not alter 11 BDNF and GDNF production, compared to vehicle control (n=3). 
